Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

Despite contributing to half of all conception hurdles, male-factor infertility is rarely talked about. For former AFL player ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

A lot of people think osteoporosis is only a women’s issue, but men can get it, too – especially as they get older, says Jim ...

NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ...

May 31 (Reuters) - Johnson & Johnson's (JNJ.N) ​prostate cancer drug Erleada used with hormone-blocking therapy six months ...

The study, which followed patients for over five ‌years, found that those ⁠who received ⁠the regimen were nine times more ...

Dr. Saransh Jain explains why erectile dysfunction is no longer just a problem of older men and what young men can do to protect their sexual health.

Testosterone treatment significantly reduces mortality among men with Klinefelter syndrome. Researcher calls for changes in guidelines to ensure more patients receive the necessary treatment. More ...

The Enhanced Games presents as the future of elite sport, but it looks like a merger with Silicon Valley, writes Colin Sheridan ...